CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma

Joseph D. Malaer, Porunelloor Mathew

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations

Abstract

CS1 (also known as CD319, CRACC and SLAMF7) was identified as an NK cell receptor regulating immune functions. It is also expressed on B cells, T cells, Dendritic cells, NK-T cells, and monocytes. CS1 is overexpressed in multiple myeloma and makes it a target for immunotherapy. A humanized anti-CS1 antibody, Elotuzumab or Empliciti has shown promising results in clinical studies. This review focuses on the biology of CS1 in NK and other hematopoietic cells and multiple myeloma. Anti-CS1 mAb can activate natural cytotoxicity of NK cells as well as enhance ADCC (antibody-dependent cell-mediated cytotoxicity) and thus makes an effective target for immunotherapy of MM.

Original languageEnglish
Pages (from-to)1637-1641
Number of pages5
JournalAmerican Journal of Cancer Research
Volume7
Issue number8
StatePublished - 1 Jan 2017

Keywords

  • Antibody-based immunotherapy
  • CRACC
  • CS1
  • Elotuzumab
  • Multiple myeloma
  • SLAMF7

Fingerprint Dive into the research topics of 'CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma'. Together they form a unique fingerprint.

Cite this